Switch to:
Also traded in: Argentina, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.49
PFE's Cash to Debt is ranked lower than
74% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. PFE: 0.49 )
Ranked among companies with meaningful Cash to Debt only.
PFE' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.90 Max: 3.47
Current: 0.49
0.22
3.47
Equity to Asset 0.39
PFE's Equity to Asset is ranked lower than
79% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. PFE: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
PFE' s Equity to Asset Range Over the Past 10 Years
Min: 0.39  Med: 0.47 Max: 0.66
Current: 0.39
0.39
0.66
Interest Coverage 13.89
PFE's Interest Coverage is ranked lower than
57% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. PFE: 13.89 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 5.24  Med: 9.80 Max: 24.84
Current: 13.89
5.24
24.84
F-Score: 6
Z-Score: 2.60
M-Score: -2.61
WACC vs ROIC
7.78%
12.10%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.03
PFE's Operating margin (%) is ranked higher than
87% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. PFE: 25.03 )
Ranked among companies with meaningful Operating margin (%) only.
PFE' s Operating margin (%) Range Over the Past 10 Years
Min: 13.89  Med: 23.40 Max: 32.43
Current: 25.03
13.89
32.43
Net-margin (%) 14.90
PFE's Net-margin (%) is ranked higher than
80% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. PFE: 14.90 )
Ranked among companies with meaningful Net-margin (%) only.
PFE' s Net-margin (%) Range Over the Past 10 Years
Min: 12.18  Med: 17.05 Max: 42.65
Current: 14.9
12.18
42.65
ROE (%) 11.56
PFE's ROE (%) is ranked higher than
65% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. PFE: 11.56 )
Ranked among companies with meaningful ROE (%) only.
PFE' s ROE (%) Range Over the Past 10 Years
Min: 9.29  Med: 12.16 Max: 28.2
Current: 11.56
9.29
28.2
ROA (%) 4.62
PFE's ROA (%) is ranked higher than
54% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. PFE: 4.62 )
Ranked among companies with meaningful ROA (%) only.
PFE' s ROA (%) Range Over the Past 10 Years
Min: 4.05  Med: 6.22 Max: 16.63
Current: 4.62
4.05
16.63
ROC (Joel Greenblatt) (%) 57.54
PFE's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. PFE: 57.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 40.57  Med: 57.28 Max: 82.01
Current: 57.54
40.57
82.01
Revenue Growth (3Y)(%) -0.20
PFE's Revenue Growth (3Y)(%) is ranked lower than
68% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. PFE: -0.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PFE' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.8  Med: 6.20 Max: 13.9
Current: -0.2
-3.8
13.9
EBITDA Growth (3Y)(%) -4.70
PFE's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. PFE: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PFE' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.7  Med: 4.50 Max: 35.3
Current: -4.7
-5.7
35.3
EPS Growth (3Y)(%) -4.10
PFE's EPS Growth (3Y)(%) is ranked lower than
65% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. PFE: -4.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PFE' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -28  Med: 1.30 Max: 90.5
Current: -4.1
-28
90.5
» PFE's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

PFE Guru Trades in Q3 2015

Leon Cooperman 4,830,595 sh (New)
Louis Moore Bacon 350,000 sh (New)
John Burbank 1,292,832 sh (New)
Lee Ainslie 6,937,928 sh (New)
Ray Dalio 345,708 sh (+337.01%)
Paul Tudor Jones 28,300 sh (+81.41%)
First Eagle Investment 6,090,294 sh (+41.13%)
Mairs and Power 3,063,915 sh (+30.30%)
Pioneer Investments 5,617,211 sh (+20.31%)
Jeremy Grantham 6,293,591 sh (+5.04%)
Murray Stahl 65,741 sh (+4.72%)
Ruane Cunniff 11,302 sh (+3.05%)
Joel Greenblatt 1,047,861 sh (+2.27%)
Diamond Hill Capital 10,380,922 sh (+1.43%)
Ken Fisher 31,926,879 sh (+0.35%)
Dodge & Cox 45,266,436 sh (+0.07%)
Robert Bruce 455,332 sh (unchged)
Richard Pzena 2,159,818 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
David Carlson 300,000 sh (unchged)
Jeff Auxier 86,322 sh (unchged)
Steven Cohen 2,200,000 sh (unchged)
NWQ Managers 217,300 sh (unchged)
Prem Watsa 235,000 sh (unchged)
Jim Simons Sold Out
Kyle Bass Sold Out
Signature Select Canadian Fund Sold Out
NWQ Managers 4,357,477 sh (-0.35%)
John Buckingham 72,589 sh (-0.66%)
T Rowe Price Equity Income Fund 12,599,315 sh (-1.08%)
John Keeley 126,755 sh (-1.78%)
Barrow, Hanley, Mewhinney & Strauss 54,274,453 sh (-1.95%)
Charles Brandes 5,863,701 sh (-3.16%)
Manning & Napier Advisors, Inc 757,703 sh (-4.54%)
Kahn Brothers 1,671,039 sh (-5.85%)
RS Investment Management 1,819,885 sh (-6.96%)
Mario Gabelli 730,005 sh (-10.96%)
Vanguard Health Care Fund 12,550,992 sh (-35.29%)
David Dreman 6,443 sh (-74.15%)
» More
Q4 2015

PFE Guru Trades in Q4 2015

David Tepper 2,412,250 sh (New)
Alan Fournier 3,027,040 sh (New)
Jim Simons 7,985,341 sh (New)
Andreas Halvorsen 7,424,690 sh (New)
Jana Partners 9,168,818 sh (New)
John Paulson 632,700 sh (New)
Lee Ainslie 11,298,953 sh (+62.86%)
Pioneer Investments 8,180,008 sh (+45.62%)
Ruane Cunniff 14,850 sh (+31.39%)
Mairs and Power 3,897,329 sh (+27.20%)
Ray Dalio 434,408 sh (+25.66%)
Paul Tudor Jones 34,900 sh (+23.32%)
T Rowe Price Equity Income Fund 14,525,000 sh (+15.28%)
John Buckingham 76,884 sh (+5.92%)
Diamond Hill Capital 10,721,361 sh (+3.28%)
Ken Fisher 32,334,417 sh (+1.28%)
Murray Stahl 65,941 sh (+0.30%)
Richard Pzena 2,161,593 sh (+0.08%)
Robert Bruce 455,332 sh (unchged)
Ronald Muhlenkamp 38,409 sh (unchged)
George Soros 1,290,000 sh (unchged)
David Carlson 300,000 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 86,224 sh (-0.11%)
Barrow, Hanley, Mewhinney & Strauss 53,862,996 sh (-0.76%)
Manning & Napier Advisors, Inc 735,031 sh (-2.99%)
Mario Gabelli 706,956 sh (-3.16%)
Charles Brandes 5,639,537 sh (-3.82%)
Jeremy Grantham 5,978,092 sh (-5.01%)
Kahn Brothers 1,569,873 sh (-6.05%)
RS Investment Management 1,634,205 sh (-10.20%)
Prem Watsa 210,000 sh (-10.64%)
Vanguard Health Care Fund 8,872,226 sh (-29.31%)
John Keeley 77,749 sh (-38.66%)
NWQ Managers 1,967,718 sh (-54.84%)
Leon Cooperman 1,295,600 sh (-73.18%)
John Burbank 161,742 sh (-87.49%)
Dodge & Cox 2,243,178 sh (-95.04%)
First Eagle Investment 135,661 sh (-97.77%)
» More
Q1 2016

PFE Guru Trades in Q1 2016

Joel Greenblatt 1,577,263 sh (New)
David Dreman 5,820 sh (New)
Paul Singer 3,925,482 sh (New)
John Burbank 3,171,356 sh (+1860.75%)
John Paulson 1,378,100 sh (+117.81%)
Jana Partners 13,460,304 sh (+46.81%)
John Keeley 104,500 sh (+34.41%)
Pioneer Investments 10,669,986 sh (+30.44%)
NWQ Managers 2,518,601 sh (+28.00%)
Mairs and Power 4,402,543 sh (+12.96%)
Ray Dalio 460,039 sh (+5.90%)
Diamond Hill Capital 11,245,591 sh (+4.89%)
David Tepper 2,512,250 sh (+4.15%)
First Eagle Investment 141,061 sh (+3.98%)
Murray Stahl 68,472 sh (+3.84%)
John Buckingham 78,483 sh (+2.08%)
T Rowe Price Equity Income Fund 14,730,900 sh (+1.42%)
Richard Pzena 2,187,104 sh (+1.18%)
RS Investment Management 1,644,965 sh (+0.66%)
Ronald Muhlenkamp 38,409 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Carlson 300,000 sh (unchged)
John Paulson 800,000 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Barrow, Hanley, Mewhinney & Strauss 53,724,766 sh (-0.26%)
Jeff Auxier 85,899 sh (-0.38%)
Manning & Napier Advisors, Inc 726,260 sh (-1.19%)
Ken Fisher 31,746,148 sh (-1.82%)
Charles Brandes 5,536,325 sh (-1.83%)
Jeremy Grantham 5,800,868 sh (-2.96%)
Kahn Brothers 1,442,543 sh (-8.11%)
Ruane Cunniff 12,442 sh (-16.22%)
Vanguard Health Care Fund 7,267,526 sh (-18.09%)
Mario Gabelli 537,011 sh (-24.04%)
Lee Ainslie 8,232,303 sh (-27.14%)
Paul Tudor Jones 14,600 sh (-58.17%)
Dodge & Cox 929,604 sh (-58.56%)
Jim Simons 2,416,341 sh (-69.74%)
Andreas Halvorsen 1,117,592 sh (-84.95%)
» More
Q2 2016

PFE Guru Trades in Q2 2016

T Rowe Price Equity Income Fund 13,941,800 sh (-5.36%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:NVSEF, NYSE:MRK, NYSE:BMY, NYSE:SNY, OTCPK:GLAXF, NYSE:ABBV, NYSE:JNJ, NYSE:LLY, OTCPK:BAYZF, NYSE:AZN, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF » details
Traded in other countries:PFE.Argentina, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, PFZ.UK,
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.

Pfizer Inc was incorporated under the laws of the State of Delaware on June 2, 1942. It is a research-based, biopharmaceutical company. The Company applies science and its resources to bring therapies to people that extend and improve their lives through the discovery, development and manufacture of healthcare products. The Company's portfolio includes medicines and vaccines, as well as many of the world's known consumer healthcare products. The Company managed its operations through four operating segments-Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; and Consumer Healthcare. Primary Care operating segment-included revenues from prescription pharmaceutical products prescribed by primary-care physicians, and included products in the following therapeutic and disease areas: Alzheimer's disease, cardiovascular (excluding pulmonary arterial hypertension) erectile dysfunction, and genitourinary, depressive disorder, and pain, respiratory and smoking cessation. Specialty Care and Oncology operating segment-was comprised of the Specialty Care business unit and the Oncology business unit. Established Products segment included revenues from prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions. Emerging Markets-included revenues from all prescription pharmaceutical products sold in emerging markets, including Asia excluding Japan and South Korea, Latin America, the Middle East, Eastern Europe, Africa, Turkey and Central Europe. Consumer Healthcare operating segment-includes revenues from non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. In 2013, products marketed by Consumer Healthcare included Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H and Robitussin. In its biopharmaceutical businesses, the Company promotes its products to healthcare providers and patients. The Company also markets directly to consumers in the U.S. through direct-to-consumer advertising that communicates the approved uses, benefits and risks of its products while motivating people to have meaningful conversations with their doctors. Its biotechnology products, including BeneFIX, ReFacto, Xyntha, Enbrel and the Prevnar family, may face competition in the future from biosimilars. The Company competes with other companies that manufacture and sell products that treat diseases or indications similar to those treated by its products. The Company is subject to regulation by national, state and local agencies in the countries in which it does business.

Ratios

vs
industry
vs
history
P/E(ttm) 30.03
PFE's P/E(ttm) is ranked lower than
54% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. PFE: 30.03 )
Ranked among companies with meaningful P/E(ttm) only.
PFE' s P/E(ttm) Range Over the Past 10 Years
Min: 7.68  Med: 16.06 Max: 30.16
Current: 30.03
7.68
30.16
Forward P/E 15.31
PFE's Forward P/E is ranked higher than
58% of the 81 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. PFE: 15.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 30.03
PFE's PE(NRI) is ranked lower than
53% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. PFE: 30.03 )
Ranked among companies with meaningful PE(NRI) only.
PFE' s PE(NRI) Range Over the Past 10 Years
Min: 9.83  Med: 19.12 Max: 30.16
Current: 30.03
9.83
30.16
Price/Owner Earnings (ttm) 19.52
PFE's Price/Owner Earnings (ttm) is ranked higher than
74% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. PFE: 19.52 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PFE' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.44  Med: 10.86 Max: 36.49
Current: 19.52
5.44
36.49
P/B 3.54
PFE's P/B is ranked lower than
60% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. PFE: 3.54 )
Ranked among companies with meaningful P/B only.
PFE' s P/B Range Over the Past 10 Years
Min: 1.32  Med: 2.40 Max: 3.61
Current: 3.54
1.32
3.61
P/S 4.48
PFE's P/S is ranked lower than
65% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. PFE: 4.48 )
Ranked among companies with meaningful P/S only.
PFE' s P/S Range Over the Past 10 Years
Min: 1.72  Med: 3.56 Max: 4.75
Current: 4.48
1.72
4.75
PFCF 16.44
PFE's PFCF is ranked higher than
67% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. PFE: 16.44 )
Ranked among companies with meaningful PFCF only.
PFE' s PFCF Range Over the Past 10 Years
Min: 5.02  Med: 13.01 Max: 17.52
Current: 16.44
5.02
17.52
POCF 14.84
PFE's POCF is ranked higher than
58% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. PFE: 14.84 )
Ranked among companies with meaningful POCF only.
PFE' s POCF Range Over the Past 10 Years
Min: 4.55  Med: 11.61 Max: 15.67
Current: 14.84
4.55
15.67
EV-to-EBIT 23.38
PFE's EV-to-EBIT is ranked lower than
57% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. PFE: 23.38 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.7  Med: 14.30 Max: 24
Current: 23.38
6.7
24
EV-to-EBITDA 15.51
PFE's EV-to-EBITDA is ranked higher than
55% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. PFE: 15.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 9.30 Max: 15.9
Current: 15.51
4.9
15.9
PEG 50.17
PFE's PEG is ranked lower than
98% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. PFE: 50.17 )
Ranked among companies with meaningful PEG only.
PFE' s PEG Range Over the Past 10 Years
Min: 0.98  Med: 3.72 Max: 1562
Current: 50.17
0.98
1562
Shiller P/E 20.99
PFE's Shiller P/E is ranked higher than
81% of the 151 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 50.39 vs. PFE: 20.99 )
Ranked among companies with meaningful Shiller P/E only.
PFE' s Shiller P/E Range Over the Past 10 Years
Min: 9.12  Med: 16.42 Max: 25.69
Current: 20.99
9.12
25.69
Current Ratio 1.44
PFE's Current Ratio is ranked lower than
75% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. PFE: 1.44 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.65 Max: 3.18
Current: 1.44
1.1
3.18
Quick Ratio 1.17
PFE's Quick Ratio is ranked lower than
69% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. PFE: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.41 Max: 2.86
Current: 1.17
0.84
2.86
Days Inventory 235.25
PFE's Days Inventory is ranked lower than
88% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. PFE: 235.25 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 181.65  Med: 229.24 Max: 344.63
Current: 235.25
181.65
344.63
Days Sales Outstanding 64.66
PFE's Days Sales Outstanding is ranked higher than
58% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.90 vs. PFE: 64.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.09  Med: 69.20 Max: 106.89
Current: 64.66
61.09
106.89
Days Payable 107.00
PFE's Days Payable is ranked higher than
71% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.26 vs. PFE: 107.00 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 73.72  Med: 95.27 Max: 179.46
Current: 107
73.72
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.15
PFE's Dividend Yield is ranked higher than
80% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. PFE: 3.15 )
Ranked among companies with meaningful Dividend Yield only.
PFE' s Dividend Yield Range Over the Past 10 Years
Min: 2.81  Med: 3.66 Max: 10.4
Current: 3.15
2.81
10.4
Dividend Payout 0.93
PFE's Dividend Payout is ranked lower than
73% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. PFE: 0.93 )
Ranked among companies with meaningful Dividend Payout only.
PFE' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.57 Max: 10.67
Current: 0.93
0.31
10.67
Dividend Growth (3y) 8.40
PFE's Dividend Growth (3y) is ranked higher than
54% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. PFE: 8.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PFE' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -14.7  Med: 13.50 Max: 22.6
Current: 8.4
-14.7
22.6
Forward Dividend Yield 3.26
PFE's Forward Dividend Yield is ranked higher than
80% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. PFE: 3.26 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.89
PFE's Yield on cost (5-Year) is ranked higher than
85% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. PFE: 4.89 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PFE' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 4.36  Med: 5.68 Max: 16.15
Current: 4.89
4.36
16.15
3-Year Average Share Buyback Ratio 5.30
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. PFE: 5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: -4.00 Max: 7.2
Current: 5.3
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.12
PFE's Price/Projected FCF is ranked higher than
82% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. PFE: 1.12 )
Ranked among companies with meaningful Price/Projected FCF only.
PFE' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.05 Max: 8.57
Current: 1.12
0.53
8.57
Price/Median PS Value 1.26
PFE's Price/Median PS Value is ranked lower than
60% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. PFE: 1.26 )
Ranked among companies with meaningful Price/Median PS Value only.
PFE' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 1.17 Max: 3.33
Current: 1.26
0.49
3.33
Earnings Yield (Greenblatt) (%) 4.32
PFE's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. PFE: 4.32 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.2  Med: 7.00 Max: 14.9
Current: 4.32
4.2
14.9
Forward Rate of Return (Yacktman) (%) 7.26
PFE's Forward Rate of Return (Yacktman) (%) is ranked higher than
50% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. PFE: 7.26 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PFE' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 7.3  Med: 13.20 Max: 22.8
Current: 7.26
7.3
22.8

More Statistics

Revenue (TTM) (Mil) $50,992
EPS (TTM) $ 1.22
Beta0.95
Short Percentage of Float0.77%
52-Week Range $28.25 - 37.19
Shares Outstanding (Mil)6,064.85

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 51,957 54,026 55,209
EPS ($) 2.40 2.61 2.88
EPS w/o NRI ($) 2.40 2.61 2.88
EPS Growth Rate
(3Y to 5Y Estimate)
6.76%
Dividends Per Share ($) 1.18 1.24 1.83
» More Articles for NYSE:PFE

Headlines

Articles On GuruFocus.com
Technology Earnings Helping Market to Gain Jul 20 2016 
US Market Indexes Achieve New Highs Jul 14 2016 
Investing in Big Pharma: Pointers on Pfizer Jul 14 2016 
John Burbank's Best Investments Jul 14 2016 
Investors Cautious in Trading as Stocks End Day Lower Jun 22 2016 
U.S. Market Indexes Gain as Investors Await UK Vote Jun 21 2016 
Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies Jun 13 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 

More From Other Websites
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ®... Jul 28 2016
4:11 pm Pfizer announces top-line results from Oral Clinical Trials for tofAcitinib in ulceratiVE... Jul 28 2016
Pfizer Announces Positive Top-Line Results from Pivotal Phase 3 Maintenance Trial of Oral XELJANZ®... Jul 28 2016
Pfizer (PFE) Stock Down, Partners with Western Oncolytics on Cancer Technology Jul 28 2016
Jim Cramer: Second-Quarter Earnings Have Been Mixed Jul 28 2016
[$$] Bristol-Myers Raises Yearly Outlook Jul 28 2016
Pfizer And Western Oncolytics Reach Immuno-Oncology Research Collaboration Jul 28 2016
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel... Jul 28 2016
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel... Jul 28 2016
AstraZeneca helped by new drugs as cholesterol pill fades Jul 28 2016
AstraZeneca a takeover target again? CEO not commenting Jul 28 2016
[$$] Specialty-Pharma Startup Nevakar Raises $55M Jul 27 2016
Options Insight: Is Pfizer the Right Prescription? Jul 27 2016
Options Insight: Is Pfizer the Right Prescription? Jul 27 2016
[$$] Pfizer Cleared to Buy Nanotech Drug Firm Bind Therapeutics Jul 27 2016
Pfizer Reaches Initial Deal Settling Celebrex, Bextra Suits Jul 27 2016
Analyst Recommendations for Roche: Buy, Hold, or Sell? Jul 27 2016
Short Sellers Get Selective on Major Pharma Jul 27 2016
Legislator: Pfizer can't complain about execution drug Jul 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)